Anxiety Disorders in a Specialty Teaching Clinic

REFERENCES

• Regier DA, M.D., MPH: Comorbidity of mental dis-orders with alcohol and other drug abuse. Results from the Epidemiological Catchment Area (ECA) Study. JAMA 264: 2511–2518, 1990
   Google Scholar
• Crowe RR: Family and twin studies of panic disorder and agoraphobia: In Noyes R Jr, Roth M, Burrows GD (eds): Handbook of Anxiety Vol. 1, Elsevier, 1988, pp. 101–114
   Google Scholar
• Noyes R: The natural history of anxiety disorders. In Noyes R Jr, Roth M, Burrows GD (eds): Handbook of Anxiety Vol. 1, Elsevier, 1988, pp. 115–133
   Google Scholar
• Weissman MM: Anxiety Disorders: An Epidemiologic Perspective. In Noyes R Jr, Roth M, Burrows GD (eds): Handbook of Anxiety Vol. 1, Elsevier, 1988, pp. 83–100
   Google Scholar
• Sheehan DV, Ballenger JC, Jacobson G: Treatment of endogenous anxiety with phobic, hysterical and hy-pochondriacal symptoms. Arch Gen Psychiatry 37:51–59, 1980
   PubMed Web of Science ®Google Scholar
• Mavissakalian M: Differential efficacy between tri-cyclic antidepressants and behavior therapy of panic disorder. In Ballenger JC (ed): Clinical Aspects of Panic Disorder. New York, Wiley-Liss, 1990
   Google Scholar
• Buigues J, Vallejo J: Therapeutic response to Phenel-zine in patients with panic disorder and agoraphobia with panic attacks. 5 Clin Psychiatry 48:55-59, 1987
   Google Scholar
• Ballenger JC, Burrows GD, DuPont RL: Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial, I: Efficacy in short term treatment. Arch Gen Psychiatry 45:413–422, 1988
   PubMedGoogle Scholar
• Mavissakalian M, Perel J: Imipramine in the treatment of agoraphobia: Dose response relationships. Am 5 Psychiatry 142:1032–1036, 1985
   Google Scholar
• Mavissakalian M, Perel 5: Imipramine dose—response relationship in panic disorder with Agoraphobia. Arch Gen Psychiatry 46:127–131, 1989
   PubMed Web of Science ®Google Scholar
• Leibowitz MR: Pharmacotherapy of social phobia: An interim report of a placebo controlled comparison of Phenelzine and Atenolol. J Clin Psychiatry 49:252–257, 1988
   Google Scholar
• Inset TR: New pharmocologic approaches to obsessive-compulsive disorder. J Clin Psychiatry 51 (suppl 10): 47–51, 1990
   Google Scholar
• Lydiard RB, Roy-Byrne PP, Ballenger JC: Recent ad-vances in psychopharmacological treatment of anxiety disorders. Hosp Community Psychiatry 39:1157–1165, 1988
   PubMedGoogle Scholar
• Michelson L, Mavissakalian M, Marchione K: Cog-nitive behavioral and psychophysiological treatments of agoraphobia: A comparative outcome investigation. Behav Ther 19:97–120, 1988
   Web of Science ®Google Scholar
• Heimberg RG, Barlow DM: Psychosocial treatments for social phobia. Psychosomatics 29:27–37, 1988
   Google Scholar
• Butler G: Exposure as a treatment for social phobia: Some instructive difficulties. Behav Res Ther 23:651–657, 1985
   PubMed Web of Science ®Google Scholar
• Foa EB, Goldstein A: Continuous exposure and com-plete response prevention in the treatment of obses-sive-compulsive neurosis. Behav Ther 9:821–829, 1978
   Web of Science ®Google Scholar
• Beck AT: Cognitive approaches to panic disorder: The-ory and therapy: In Rachman S. Maser JD (eds): Panic: Psychologic perspectives. New Jersey, Lawrence Erl-baum Associates, 1988, pp 91–109
   Google Scholar
• Barlow DH: Long term outcome for patients with panic disorder treated with cognitive-behavioral ther-apy. J Clin Psychiatry 51:12 (suppl A): 17–23, 1990
   Google Scholar
• Mavissakalian M, Jones B: Antidepressant drugs plus exposure treatment of Agoraphobia/Panic and obses-sive-compulsive disorders. International Review of Psychiatry 1:275–282, 1989
   Google Scholar
• Mavissakalian M.: The mutually potentiating effects of Imipramine and exposure in agoraphobia. In Hand I, Wittchen HU (eds): Panic and Phobias Vol. II, New York, Springer-Verlag, 1988, pp 36–43
   Google Scholar
• Marks IM, Mathews AM: Brief standard self rating for phobic patients. Behav Res Ther 17:263–267, 1979
   PubMed Web of Science ®Google Scholar
• Beck AT, War CH, Hedelson M: An inventory for measuring depression. Arch Gen Psychiatry 4:53–64, 1961
   Web of Science ®Google Scholar
• Zurtg WINK: A rating instrument for anxiety disor-ders. Psychosomatics 12:371–379, 1971
   Google Scholar
• Hodgson RJ, Rachman J: Obsessional-compulsive complaints. Behav Res Ther 15:389–395, 1977
   PubMed Web of Science ®Google Scholar
• Allen JJ, Tune GS: The Lynfield obsessional/compul-sive questionnaires. Scott Med J 20:21–24, 1975
   PubMed Web of Science ®Google Scholar
• Mavissakalian M: Sequential combination of Imipra-mine and self directed exposure in the treatment of panic disorder and agoraphobia. J Clin Psychiatry 51:184–188, 1990
   Google Scholar
• Aronson TA: A naturalistic study of lmipramine in panic disorder and agoraphobia. Am J Psychiatry 144:1014–1019, 1987
   Google Scholar
• Marks IM: Imipramine and brief therapist-aided ex-posure in agoraphobics having self exposure home-work. Arch Gen Psychiatry 40:153–162, 1983
   PubMed Web of Science ®Google Scholar
• Mavissakalian M, Michelson L: Relative and combined effectiveness of therapist assisted in vivo exposure and Imipramine. J Clin Psychiatry 47:117–122, 1986a
   PubMed Web of Science ®Google Scholar
• Ghash A, Marks IM: Self-treatment of agoraphobia by exposure. Behav Ther 18:3–16, 1987
   Google Scholar
• Welkowitz LA: Cognitive-behavior therapy for panic disorder delivered by psychopharmacologically ori-ented clinicians. J Nerv Ment Dis 179:473–477, 1991
   Google Scholar
• Gournay KJM: The base for exposure treatment in Agoraphobia: Some indicators for nurse therapists and community psychiatric nurses. J Adv Nurs 16:82–91, 1991
   PubMed Web of Science ®Google Scholar